Valuation: Zai Lab Limited

Market Cap 2.74B 21.49B 2.45B 2.26B 2.05B 3.82B 260B 3.89B 26.92B 10.81B 137B 10.28B 10.06B 432B P/E 2026 *
-9.99x
P/E 2027 * -9.97x
Enterprise Value 2.28B 17.9B 2.04B 1.88B 1.7B 3.18B 217B 3.24B 22.42B 9B 114B 8.56B 8.38B 359B EV / Sales 2026 *
5.27x
EV / Sales 2027 * 4.3x
Free-Float
94.05%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Zai Lab Limited

1 day-1.75%
1 week-2.31%
Current month-15.84%
1 month-15.84%
3 months+22.41%
6 months+5.46%
Current year+27.25%
1 week 17.15
Extreme 17.15
19.22
1 month 16.71
Extreme 16.71
20.94
Current year 12.31
Extreme 12.31
21.42
1 year 12.31
Extreme 12.31
21.42
3 years 10.56
Extreme 10.56
35.5
5 years 10.56
Extreme 10.56
82.5
10 years 10.56
Extreme 10.56
151.2
Manager TitleAgeSince
Chief Executive Officer 61 01/04/2014
Director of Finance/CFO 58 07/07/2023
President 62 01/12/2022
Director TitleAgeSince
Chairman 61 01/04/2014
Director/Board Member 83 01/01/2017
Director/Board Member 75 01/01/2017
Change 5-day change 1-year change 3-year change Capi.($)
-1.75%-2.31% - - 2.74B
Average -1.75%
Weighted average by Cap. -1.75%

Financials

2026 *2027 *
Net sales 433M 3.39B 388M 356M 323M 604M 41.09B 615M 4.25B 1.71B 21.61B 1.62B 1.59B 68.16B 548M 4.3B 491M 452M 409M 765M 52.05B 779M 5.39B 2.16B 27.38B 2.06B 2.01B 86.35B
Net income -241M -1.89B -216M -198M -180M -336M -22.85B -342M -2.36B -949M -12.02B -903M -884M -37.91B -220M -1.72B -197M -181M -164M -306M -20.85B -312M -2.16B -866M -10.97B -824M -807M -34.59B
Net Debt -458M -3.59B -410M -377M -342M -639M -43.45B -651M -4.5B -1.8B -22.86B -1.72B -1.68B -72.09B -381M -2.99B -341M -314M -284M -531M -36.16B -541M -3.74B -1.5B -19.02B -1.43B -1.4B -59.98B
Projected Income Statement - Annual - Zai Lab Limited
Logo Zai Lab Limited
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Employees
1,784
Date Price Change Volume
30/10/26 HK$17.37 -1.75% 2,602,800
29/10/26 HK$17.68 -2.80% 4,070,800
28/10/26 HK$18.19 +0.06% 3,718,303
27/10/26 HK$18.18 -3.14% 5,529,500
26/10/26 HK$18.77 +5.57% 6,269,500
Trader
Investor
-
Global
-
Quality
ESG MSCI
A
MarketScreener Ratings - Zai Lab Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
22.07USD
Average target price
33.48USD
Spread / Average Target
+51.68%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Zai Lab Limited